Core Insights - Editas Medicine has demonstrated therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells using a proprietary targeted lipid nanoparticle (tLNP) approach, supporting its potential as a novel treatment for sickle cell disease and beta thalassemia [1][2][3] Group 1: Research Findings - The proprietary tLNP formulation achieved up to 47% HBG1/2 editing levels in non-human primates (NHPs) and 48% in humanized mice, exceeding the ≥25% threshold required for therapeutic benefit [2] - Preliminary biodistribution data indicates significant liver de-targeting with Editas' tLNP compared to standard lipid nanoparticles [2] Group 2: Clinical Development - The in vivo HSC program targets HBG1/2 promoters to mimic hereditary persistence of fetal hemoglobin (HPFH) and utilizes AsCas12a for high efficiency and minimized off-target editing [3] - The investigational medicine reni-cel has shown robust increases in fetal hemoglobin (HbF) and total hemoglobin (Hb) in clinical trials [3] Group 3: Presentation Details - Editas Medicine presented these findings at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) on May 14, 2025, with a session focused on translational applications of gene editing [4] - Additional poster presentations included topics on improved LNP targeting ligands and chemically modified AsCas12a guide RNAs [5][6] Group 4: Company Overview - Editas Medicine is focused on translating CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into in vivo medicines for serious diseases [7] - The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines, holding exclusive licenses for key CRISPR patents [7]

Summary of Editas' Conference Call Company Overview - **Company**: Editas Medicine - **Industry**: Biotechnology, specifically focusing on gene editing and therapy Key Points and Arguments Focus on In Vivo Development - Editas aims to be a premier in vivo gene editing company, refining its focus since the CEO's arrival three years ago [5] - The company has generated promising data in in vivo gene editing, particularly for sickle cell disease, which is seen as a significant opportunity [6][7] Market Potential and Treatment Efficacy - In vivo gene editing is expected to expand the market and reduce patient burden compared to ex vivo therapies [6] - The company believes that the efficacy bar for in vivo treatments is on par or better than ex vivo options, allowing for a larger patient population [9] Preclinical Data and Optimization - Editas is applying learnings from its ex vivo program to optimize its in vivo gene editing approach, focusing on delivery mechanisms [10][11] - Proprietary TLNP technology is showing great potential in preclinical settings [11] Business Development and Pipeline Expansion - The company is exploring additional investments and partnerships to expand its pipeline, particularly in in vivo applications [13][17] - Editas is focused on being best-in-class in vivo gene therapy, with a strategic approach to target functional proteins [15][16] Financial Position and Capital Efficiency - Editas has a cash runway extending into Q2 2027, providing breathing room to advance its in vivo programs [19][21] - The company is being capital efficient, particularly in managing wind-down costs from previous programs [26] Licensing Agreements and Intellectual Property - Current licensing agreements remain unaffected by recent legal decisions, and Editas is open to new licensing opportunities [28][29] Upcoming Data and Milestones - Editas presented data at ASGCT, showing over 80% reduction in a disease biomarker in its liver program [32] - The company plans to declare two drug candidates by mid-2025 and file an IND for one candidate in 2026, with potential human proof of mechanism expected by late 2026 to early 2027 [36] Conclusion - Editas is focused on advancing its in vivo gene editing capabilities while maintaining a strong financial position and exploring new partnerships to enhance its pipeline [41]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Editas Medicine (EDIT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Editas Medicine is one of 1001 individual stocks in the Medical sector. Collectiv ...

Editas Medicine (EDIT) reported an adjusted loss of 43 cents per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 51 cents. The adjusted figure excluded the effect of restructuring and impairment charges in the reported quarter. The company had incurred a loss of 76 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $4.7 million in the reported quarter, up significantl ...

Core Insights - Editas Medicine has presented in vivo proof of concept data for a potential first-in-class treatment targeting an undisclosed liver condition, showcasing significant advancements in gene editing technology [1][4]. Group 1: In Vivo Editing Strategy - The company utilized lipid nanoparticles (LNPs) to deliver CRISPR/Cas RNA cargo for editing a liver target gene, resulting in the upregulation of the target gene and a meaningful reduction in disease-specific biomarkers in mice [2][7]. - A dose-response study demonstrated approximately 70% editing of the target gene in a disease-specific mouse model, leading to over 80% reduction in disease biomarkers [7]. Group 2: Presentation Details - Editas Medicine will present its findings in a poster session at the 28th Annual Meeting of the American Society of Gene and Cell Therapy on May 14, 2025, with additional data to be shared at the TIDES USA 2025 conference on May 21 [5][4]. Group 3: Future Developments - The company is making significant progress towards clinical applications and plans to disclose the specific disease target and development candidate later this year [4].

Core Insights - Editas Medicine reported a quarterly loss of $0.43 per share, better than the Zacks Consensus Estimate of a loss of $0.51, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of 15.69% [1] - The company generated revenues of $4.66 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 385.21%, compared to $1.14 million in the same quarter last year [2] - Editas shares have increased by approximately 14.2% since the beginning of the year, contrasting with a -3.8% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $0.98 million, and for the current fiscal year, it is -$1.53 on revenues of $6.74 million [7] - The estimate revisions trend for Editas is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Editas belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 _______________________________ EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) _______________________________ FORM 10-Q _______________________________ (Mark One) ☐ QUARTERLY R ...

"We achieved notable progress in the first quarter, advancing our mission and strategy to become a leader in in vivo gene editing. This momentum was fueled by recent scientific breakthroughs that bolster our confidence in the near-term potential of CRISPR-based in vivo gene editing therapies," said Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. "I'm proud of the strides made by the Editas team in driving our in vivo gene editing programs, which we believe could unl ...

Core Insights - Editas Medicine is advancing its in vivo gene editing programs, focusing on CRISPR-based therapies, with significant progress reported in the first quarter of 2025 [2][3] - The company plans to present preclinical data at the ASGCT and TIDES conferences, showcasing its innovative approaches in gene editing [6][11] - Editas maintains a strong cash position, with sufficient funds to support operations into the second quarter of 2027 [9] Financial Performance - For Q1 2025, Editas reported a net loss of $76.1 million, or $0.92 per share, compared to a net loss of $62.0 million, or $0.76 per share, in Q1 2024 [13][21] - Collaboration and other research and development revenues increased to $4.7 million in Q1 2025 from $1.1 million in Q1 2024, primarily due to the recognition of deferred revenue from a collaboration agreement [13] - Research and development expenses decreased to $26.6 million in Q1 2025 from $48.8 million in Q1 2024, attributed to the discontinuation of the reni-cel program [13][18] Upcoming Developments - Editas is set to share in vivo preclinical data on targeted lipid nanoparticles for gene delivery to hematopoietic stem and progenitor cells at ASGCT on May 14, 2025 [4][6] - The company will also present data on CRISPR editing to upregulate liver protein expression and reduce disease-associated biomarkers [5][7] - Editas aims to declare two in vivo gene editing development candidates by mid-2025, one targeting hematopoietic stem cells and another for liver cells [1][11] Leadership Changes - Amy Parison has been appointed as Chief Financial Officer, bringing over 18 years of experience in financial management within the life sciences sector [2][8] Intellectual Property - Editas remains confident in its intellectual property position, particularly regarding its CRISPR/Cas9 and Cas12a patent estates, following a recent court ruling [12]

Core Viewpoint - Editas Medicine, Inc. announced a partial affirmation and partial vacate of a previous decision by the U.S. Court of Appeals regarding patent interference related to CRISPR/Cas9 editing, with the case remanded back to the Patent Trial and Appeal Board (PTAB) for further review [1] Group 1: Legal and Patent Developments - The U.S. Court of Appeals for the Federal Circuit has affirmed-in-part and vacated-in-part the PTAB's decision regarding patents for CRISPR/Cas9 editing in human cells involving the University of California, University of Vienna, Emmanuelle Charpentier, and the Broad Institute [1] - Editas Medicine's in-licensed patents covering CRISPR/Cas12a are not affected by this decision and are not involved in the ongoing interference proceedings [1] Group 2: Company Strategy and Intellectual Property - The company remains confident in the strength of its intellectual property (IP) portfolio, which is expected to generate significant value now and in the future [2] - Editas holds a large portfolio of foundational U.S. and international patents, including exclusive licenses for Cas9 and Cas12a patent estates, which are crucial for developing human medicines [2] - The foundational IP includes issued patents covering fundamental aspects of CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells, essential for CRISPR-based medicines [2] Group 3: Company Mission and Focus - Editas Medicine is focused on translating the potential of CRISPR/Cas12a and CRISPR/Cas9 systems into a pipeline of in vivo medicines for serious diseases [3] - The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines for a broad class of diseases [3]